Personalised home hazard assessments and interventions will help to prevent older and at-risk people from suffering from falls, according to new NICE guideline ...

There is a simple discount patient access scheme for leniolisib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The technology, which is capable of movements more precise than the human hand, has the potential to transform care for patients being operated on by surgeons in specialist NHS centres. Patient ...

Leniolisib is recommended, within its marketing authorisation, for treating activated phosphoinositide 3‑kinase delta syndrome (APDS) in people 12 years and over. Leniolisib is recommended only if the ...

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technology being evaluated. If it is ...

In development GID-IND10298 Expected publication date: TBC Register as a stakeholder ...

Tools to help you put the guidance into practice.

In development GID-IND10299 Expected publication date: TBC Register as a stakeholder ...

Coding and clinical classification codes for this guidance. This guidance replaces NICE interventional procedures guidance on balloon disimpaction of the baby’s head at emergency caesarean during the ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy TA1055 16 April 2025 16 April 2025 ...

Suggested remit: To appraise the clinical and cost effectiveness of tolebrutinib within its marketing authorisation for treating non-relapsing secondary progressive multiple sclerosis.